CL2021000044A1 - Composiciones que comprenden 2-((1-(2(4-fluorofenil)-2-oxoetil) piperidin-4-il)metil)isoindolin-1-ona para tratar la esquizofrenia (divisional solicitud no. 1376-2017) - Google Patents

Composiciones que comprenden 2-((1-(2(4-fluorofenil)-2-oxoetil) piperidin-4-il)metil)isoindolin-1-ona para tratar la esquizofrenia (divisional solicitud no. 1376-2017)

Info

Publication number
CL2021000044A1
CL2021000044A1 CL2021000044A CL2021000044A CL2021000044A1 CL 2021000044 A1 CL2021000044 A1 CL 2021000044A1 CL 2021000044 A CL2021000044 A CL 2021000044A CL 2021000044 A CL2021000044 A CL 2021000044A CL 2021000044 A1 CL2021000044 A1 CL 2021000044A1
Authority
CL
Chile
Prior art keywords
isoindolin
oxoethyl
piperidin
fluorophenyl
methyl
Prior art date
Application number
CL2021000044A
Other languages
English (en)
Inventor
Remy Luthringer
Masahiro Okuyama
Nadine Noel
Sandra Werner
Original Assignee
Minerva Neurosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Minerva Neurosciences Inc filed Critical Minerva Neurosciences Inc
Publication of CL2021000044A1 publication Critical patent/CL2021000044A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La divulgación proporciona un nuevo polimorfo del Compuesto (I): monoclorhidrato de 2-((1-(2-(4- fluorofenil)-2-oxoetil) piperidin-4- il)metil)isoindolin-1-ona dihidratado, es decir, la Forma (A) del Compuesto (I)·HCl·2H2O. Se divulgan también composiciones farmacéuticas que comprenden la Forma (A) del Compuesto (I)·HCl·2H2O y métodos de tratamiento relacionados.
CL2021000044A 2014-12-02 2021-01-07 Composiciones que comprenden 2-((1-(2(4-fluorofenil)-2-oxoetil) piperidin-4-il)metil)isoindolin-1-ona para tratar la esquizofrenia (divisional solicitud no. 1376-2017) CL2021000044A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462086691P 2014-12-02 2014-12-02
US201562248071P 2015-10-29 2015-10-29
CL2017001376A CL2017001376A1 (es) 2014-12-02 2017-05-30 Composiciones que comprenden 2-((1-(2(4-fluorofenil)-2-oxoetil) piperidin-4-il)metil)isoindolin-1-ona para tratar la esquizofrenia

Publications (1)

Publication Number Publication Date
CL2021000044A1 true CL2021000044A1 (es) 2021-06-04

Family

ID=54848909

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2017001376A CL2017001376A1 (es) 2014-12-02 2017-05-30 Composiciones que comprenden 2-((1-(2(4-fluorofenil)-2-oxoetil) piperidin-4-il)metil)isoindolin-1-ona para tratar la esquizofrenia
CL2021000044A CL2021000044A1 (es) 2014-12-02 2021-01-07 Composiciones que comprenden 2-((1-(2(4-fluorofenil)-2-oxoetil) piperidin-4-il)metil)isoindolin-1-ona para tratar la esquizofrenia (divisional solicitud no. 1376-2017)

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CL2017001376A CL2017001376A1 (es) 2014-12-02 2017-05-30 Composiciones que comprenden 2-((1-(2(4-fluorofenil)-2-oxoetil) piperidin-4-il)metil)isoindolin-1-ona para tratar la esquizofrenia

Country Status (26)

Country Link
US (7) US9458130B2 (es)
EP (2) EP3227273B1 (es)
JP (4) JP2018501217A (es)
KR (1) KR102620681B1 (es)
CN (2) CN107567444A (es)
AU (4) AU2015355226B2 (es)
BR (1) BR112017011555B1 (es)
CA (1) CA2968977A1 (es)
CL (2) CL2017001376A1 (es)
CO (1) CO2017005498A2 (es)
DK (1) DK3227273T3 (es)
EA (1) EA201791226A1 (es)
ES (1) ES2910528T3 (es)
HU (1) HUE058212T2 (es)
IL (4) IL280052B2 (es)
MX (1) MX385586B (es)
MY (1) MY185516A (es)
PE (1) PE20171646A1 (es)
PH (1) PH12017501007B1 (es)
PL (1) PL3227273T3 (es)
PT (1) PT3227273T (es)
SG (1) SG11201704332YA (es)
TW (1) TWI694069B (es)
UA (1) UA122780C2 (es)
WO (1) WO2016089766A1 (es)
ZA (1) ZA201703481B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2910528T3 (es) * 2014-12-02 2022-05-12 Minerva Neurosciences Inc Composiciones que comprenden 2-((1-(2(4-fluorofenil)-2-oxoetil)piperidin-4-il)metil)isoindolin-1-ona para tratar la esquizofrenia
SG11201810358YA (en) * 2016-05-25 2018-12-28 Mitsubishi Tanabe Pharma Corp Compositions and methods for treating negative symptoms in non-schizophrenic patients
IL308650B2 (en) * 2017-06-21 2025-08-01 Minerva Neurosciences Inc Gastro-resistant controlled release oral dosage forms
JP7811085B2 (ja) 2017-09-01 2026-02-04 ピーティーシー セラピューティクス エムピー，インコーポレイテッド セピアプテリンを含む医薬組成物及びその使用
CN107721988A (zh) * 2017-10-31 2018-02-23 无锡福祈制药有限公司 具有抗炎活性的异吲哚‑1‑酮类化合物
KR102886241B1 (ko) * 2018-08-21 2025-11-14 미쓰비시 타나베 파마 코퍼레이션 음성 증상 및 장애를 치료하고, 신경가소성을 증가시키고, 신경보호를 촉진시키기 위한 롤루페리돈의 용도
TWI841545B (zh) * 2018-12-12 2024-05-11 日商田邊三菱製藥股份有限公司 耐胃性控制釋放經口劑型
EP3990113A1 (en) 2019-06-28 2022-05-04 Teva Czech Industries s.r.o. Solid state forms of roluperidone and salts thereof
IL298323B2 (en) 2020-05-20 2023-10-01 Univ Illinois A method for treating lysosomal storage disease using histatin peptides
CN116251078B (zh) * 2021-12-09 2025-12-19 河北以岭医药研究院有限公司 一种盐酸度洛西汀肠溶胶囊及其制备方法
JP2025505261A (ja) 2022-02-14 2025-02-21 ミネルヴァ ニューロサイエンシズ，インコーポレーテッド 統合失調症患者における再発の予防におけるロルペリドンの使用
WO2025090588A1 (en) 2023-10-24 2025-05-01 Minerva Neurosciences, Inc. Roluperidone for the treatment of lysosomal storage disorders and their symptoms

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
EP0325063B1 (en) 1988-01-21 1994-03-09 Merrell Dow Pharmaceuticals Inc. Use of 1,4-disubstituted-piperidinyl compounds in the manufacture of a medicament for the treatment of insomnia
EP0497843A4 (en) 1989-10-27 1992-09-23 The Du Pont Merck Pharmaceutical Company (n-phthalimidoalkyl) piperidines
FR2797643B1 (fr) 1999-08-17 2003-06-06 Rhodia Chimie Sa Utilisation composes terpeniques polyoxypropylenes/ polyoxyethylenes comme agent de degraissage de surfaces dures
NZ521576A (en) * 2000-02-29 2005-06-24 Mitsubishi Pharma Corp Novel cyclic amide derivatives
EP1372611B1 (en) 2001-03-26 2006-05-17 Novartis AG Pharmaceutical composition comprising a poorly water-soluble staurosporine, a surfactant and a water-soluble polymer
PE20061490A1 (es) 2005-06-06 2007-02-09 Merck Sharp & Dohme Derivados de ciclohexanosulfonilo como inhibidores del transportador de glicina glyt1
CA2569776A1 (en) 2006-02-17 2007-08-17 Kos Life Sciences, Inc. Low flush niacin formulation
GB2462611A (en) 2008-08-12 2010-02-17 Cambridge Lab Pharmaceutical composition comprising tetrabenazine
WO2012012542A1 (en) * 2010-07-20 2012-01-26 Cyrenaic Pharmaceuticals, Inc. Methods of use of cyclic amide derivatives to treat schizophrenia
US8937900B2 (en) * 2010-07-20 2015-01-20 Qualcomm Incorporated Enhancing pilot channel transmission in TD-SCDMA multicarrier systems using secondary carrier frequencies
CN103108548A (zh) 2010-07-20 2013-05-15 昔勒尼药品公司 使用环酰胺衍生物治疗σ受体介导的病症的方法
EP2468264A1 (en) 2010-12-27 2012-06-27 Laboratorios Liconsa, S.A. Oral pharmaceutical tablet for controled release of mesalazine and process for obtaining it
US9737531B2 (en) 2012-07-12 2017-08-22 Glytech, Llc Composition and method for treatment of depression and psychosis in humans
KR20140045925A (ko) * 2011-03-17 2014-04-17 루핀 리미티드 선택적 세로토닌 재흡수 억제제의 방출조절형 약제학적 조성물
WO2015191554A1 (en) 2014-06-09 2015-12-17 Intra-Cellular Therapies, Inc. Compounds and methods of use to treat schizophrenia
ES2910528T3 (es) 2014-12-02 2022-05-12 Minerva Neurosciences Inc Composiciones que comprenden 2-((1-(2(4-fluorofenil)-2-oxoetil)piperidin-4-il)metil)isoindolin-1-ona para tratar la esquizofrenia
SG11201810358YA (en) 2016-05-25 2018-12-28 Mitsubishi Tanabe Pharma Corp Compositions and methods for treating negative symptoms in non-schizophrenic patients
IL308650B2 (en) 2017-06-21 2025-08-01 Minerva Neurosciences Inc Gastro-resistant controlled release oral dosage forms
KR102886241B1 (ko) 2018-08-21 2025-11-14 미쓰비시 타나베 파마 코퍼레이션 음성 증상 및 장애를 치료하고, 신경가소성을 증가시키고, 신경보호를 촉진시키기 위한 롤루페리돈의 용도

Also Published As

Publication number Publication date
IL301320A (en) 2023-05-01
EP4063357A1 (en) 2022-09-28
IL252347B (en) 2021-01-31
CO2017005498A2 (es) 2017-09-20
JP2022105159A (ja) 2022-07-12
EP3227273B1 (en) 2022-02-09
PT3227273T (pt) 2022-04-06
AU2015355226B2 (en) 2020-04-02
KR20170106310A (ko) 2017-09-20
KR102620681B1 (ko) 2024-01-04
US20230201184A1 (en) 2023-06-29
NZ732033A (en) 2023-10-27
IL301320B1 (en) 2024-07-01
US20160152597A1 (en) 2016-06-02
JP2025004090A (ja) 2025-01-14
BR112017011555B1 (pt) 2023-10-03
IL301320B2 (en) 2024-11-01
AU2020204286A1 (en) 2020-07-16
US20200022968A1 (en) 2020-01-23
CN111110677A (zh) 2020-05-08
IL313572A (en) 2024-08-01
US20210228561A1 (en) 2021-07-29
MY185516A (en) 2021-05-19
US20250195494A1 (en) 2025-06-19
TWI694069B (zh) 2020-05-21
AU2021229240A1 (en) 2021-10-07
MX2017007065A (es) 2017-12-18
JP2018501217A (ja) 2018-01-18
BR112017011555A2 (pt) 2018-01-09
CA2968977A1 (en) 2016-06-09
PE20171646A1 (es) 2017-11-13
ES2910528T3 (es) 2022-05-12
US20170042877A1 (en) 2017-02-16
CN107567444A (zh) 2018-01-09
AU2020204286B2 (en) 2021-06-17
JP7069253B2 (ja) 2022-05-17
UA122780C2 (uk) 2021-01-06
TW201632511A (zh) 2016-09-16
AU2023258386A1 (en) 2023-11-23
AU2021229240B2 (en) 2023-08-24
HUE058212T2 (hu) 2022-07-28
US20180153871A1 (en) 2018-06-07
US10258614B2 (en) 2019-04-16
PH12017501007A1 (en) 2017-12-18
MX385586B (es) 2025-03-18
EP4063357B1 (en) 2025-12-31
SG11201704332YA (en) 2017-06-29
WO2016089766A1 (en) 2016-06-09
ZA201703481B (en) 2023-12-20
NZ770365A (en) 2023-10-27
US10799493B2 (en) 2020-10-13
US9458130B2 (en) 2016-10-04
IL280052B1 (en) 2023-05-01
IL280052B2 (en) 2023-09-01
CL2017001376A1 (es) 2018-02-16
PH12017501007B1 (en) 2024-07-03
US9730920B2 (en) 2017-08-15
DK3227273T3 (da) 2022-05-02
EP3227273A1 (en) 2017-10-11
PL3227273T3 (pl) 2022-05-30
IL280052A (en) 2021-03-01
JP2020172531A (ja) 2020-10-22
EA201791226A1 (ru) 2017-09-29
AU2023258386B2 (en) 2025-10-23
AU2015355226A1 (en) 2017-06-08
IL252347A0 (en) 2017-07-31

Similar Documents

Publication Publication Date Title
CL2021000044A1 (es) Composiciones que comprenden 2-((1-(2(4-fluorofenil)-2-oxoetil) piperidin-4-il)metil)isoindolin-1-ona para tratar la esquizofrenia (divisional solicitud no. 1376-2017)
MX381417B (es) Inhibidores de glucosidasa.
CL2016002072A1 (es) 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer
PH12016502382A1 (en) Substituted indazole compounds as irak4 inhibitors
MX381342B (es) Compuestos terapeuticos inhibidores.
MX373373B (es) Inhibidores de desmetilasa-1 específica de lisina.
CY1122264T1 (el) Ppar ενωσεις για χρηση στην αντιμετωπιση των ινωτικων νοσων
GEAP201914554A (en) A novel crystalline form of a benzimidazole derivative and a preparation method thereof
MX377845B (es) Inhibidores de calicreína plasmática humana.
MX376056B (es) Pirimidinonas como inhibidores del factor xia.
HUE051693T2 (hu) 5-Klór-N4-[2-(dimetilfoszforil)-fenil]-N2-{2-metoxi-4-[4-(4-metilpiperazin-1-il)-piperidin-1-il] -pirimidin-2,4-diamin kristályos formái
HRP20181698T1 (hr) 2-amino-6-(difluormetil)-5,5-difluor-6-fenil-3,4,5,6-tetrahidropiridini kao inhibitori bace1
EA201691600A1 (ru) Дигидропиридиноновые ингибиторы mgat2 для применения в лечении метаболических нарушений
MX2016014939A (es) Derivados de carboxamida.
MX385687B (es) Inhibidores de calicreína plasmática humana.
EA201791480A1 (ru) Новые производные бензимидазола в качестве антигистаминных агентов
EA201790687A1 (ru) Хинолинкарбоксамиды для применения в лечении множественной миеломы
EP2948441A4 (en) PROCESS FOR PREPARATION OF 1- (4- (4- (3,4-DICHLOR-2-FLUORO-PHENYL AMINO) -7-METHOXYCHINAZOLINE-6-YLOXY) PIPERIDIN-1-YL) PROP-2-EN-1-ON
MA47193A (fr) Formes posologiques solides d'inhibiteurs bace1 2-amino-6-(difluorométhyl)-5,5-difluoro-6-phényl-3,4,5,6-tétrahydropyridine
PL407398A1 (pl) 1,1-ditlenek 2-[2-(4-fenylopiperazyn-1-ylo)-2-oksoetylo]-4-hydroksy-3-(4-metylobenzoilo)-2H-1,2-benzotiazyny o aktywności przeciwbólowej i przeciwzapalnej oraz sposób jego wytwarzania
PL407399A1 (pl) 1,1-ditlenek 2-[2-(4-fenylopiperazyn-1-ylo)-2-oksoetylo]-3-(4-fluorobenzoilo)-4-hydroksy-2H-1,2-benzotiazyny o aktywności przeciwzapalnej i przeciwbólowej oraz sposób jego wytwarzania